Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches

Area of Science:

• Cancer Biology
• Genetics
• Pharmacology

Background:

• Direct targeting of oncogenic drivers is often unfeasible in cancer due to a lack of druggable targets.
• Synthetic lethality (SL) provides an indirect strategy to target cancer drivers, as seen with PARP inhibitors in BRCA-mutated tumors.
• Existing methods for identifying SL interactions face challenges in clinical translation.

Purpose of the Study:

• To review recent advancements in synthetic lethality (SL) relationships in cancer.
• To explore the integration of epigenetic regulation and epigenetic drugs (epidrugs) with SL strategies.
• To highlight opportunities for developing more precise and effective targeted cancer interventions.

Main Methods:

• Review of high-throughput perturbation screens and multi-omics technologies for SL identification.
• Analysis of computational models for predicting SL interactions and biological complexity.
• Integration of experimental and computational approaches to characterize cancer cell vulnerabilities.

Main Results:

• Advances in screening and multi-omics have improved understanding of SL relationships.
• Computational models enhance the prediction of SL interactions.
• Epigenetic drugs offer potential for targeted cancer interventions with minimized off-target effects.

Conclusions:

• Integrating SL with epigenetic regulation and epidrugs presents a promising avenue for targeted cancer therapy.
• Future efforts should focus on identifying novel SL interactions and consolidating existing knowledge.
• Strengthening the foundation of SL research through integrated approaches is critical for clinical translation.